SyzOnc is an integrated oncology platform and therapeutics company developing next generation treatments for solid tumor patients. Our therapies will provide patients with new approaches and clinicians with new tools to fight devastating solid tumors.

Most people diagnosed with solid tumors (like sarcomas or liver cancer) have few effective treatment options. The standard of care is currently non-curative. These cancers quickly evolve resistance to today’s standard treatments, including chemotherapy and immunotherapy. The result? Too many patients face relapse and limited survival. The reason is simple but overlooked: cancer isn’t just about cancer cells. Tumors are ecosystems made up of cancer cells, immune cells, and a protective physical infrastructure called the extracellular matrix (ECM). These elements work together to help the tumor grow, evade the immune system, and block treatments. 

Choosing anti-cancer molecular targets based on oncogenic driver mutations, or a singular function such as “ability to enhance proliferation”, invites tumors to evolve workarounds that make these point solutions fail. Tumors are not static, they evolve, and we need solutions that are powerful enough to eliminate their ability to rebound. Furthermore, immuno-oncology fails for many cancer types because it is ineffective in solid tumor microenvironments where the extracellular matrix is tumor protective. Our approach to solid tumors uses AI/ML tools to target critical features of tumor biology untapped by the traditional pharma pipeline, specifically the 3D matrix-rich tumor ecosystem. Our unique next generation targets and rapid phenotypic drug screening approach will bring clinical success to solid tumor patients.

We developed a platform to eliminate the bench to bedside failures in target discovery that have plagued oncology. It integrates public and proprietary tumor ecosystem data encompassing several key aspects of tumor biology: cancer cells, matrix, and immune cells. This approach will reveal novel “triple threat” targets that control all three areas, simultaneously. Our first small molecules are under development and we look forward to delivering them to solid tumor patients.